Taiho, a firm engaged in the research, development, production, distribution, and marketing of pharmaceutical products, agreed to acquire Cullinan Pearl, a subsidiary of Cullinan Oncology, a biopharmaceutical company, for $275m. “Importantly, the structure of the agreement provides the opportunity to efficiently establish our own commercial infrastructure, which will also be leveraged for our future programs. The transaction payments, reduced development expense, and potential ongoing revenue stream upon future commercialization will help us to devote greater resources to advance our robust pipeline of assets across a wide range of modalities, each with the potential to be the first or best in their class, to deliver on our promise to bring new therapeutic solutions to patients with cancer," Nadim Ahmed, Cullinan Oncology CEO.